Accessibility Menu
Enveric Biosciences logo

Enveric Biosciences

(NASDAQ) ENVB

Current Price$1.65
Market Cap$5.89M
Since IPO (2020)-100%
5 Year-100%
1 Year-90%
1 Month-44%

Enveric Biosciences Financials at a Glance

Market Cap

$5.89M

Revenue (TTM)

$0.00

Net Income (TTM)

-$8.22M

EPS (TTM)

-$27.35

P/E Ratio

-0.06

Dividend

$0.00

Beta (Volatility)

1.46 (Average)

Price

$1.65

Volume

64,750.194

Open

$1.64

Previous Close

$1.60

Daily Range

$1.62 - $1.73

52-Week Range

$1.60 - $17.64

Estimated Earnings Date

Aug 17, 2026

ENVB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Enveric Biosciences

Industry

Pharmaceuticals

Employees

6

CEO

Joseph Tucker, PhD

Headquarters

Naples, FL 34103, US

ENVB Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-183%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.89M

Shares Outstanding

3.68M

Volume

64.75K

Avg. Volume

3.75M

Financials (TTM)

Gross Profit

-$200.86K

Operating Income

-$8.77M

EBITDA

-$8.57M

Operating Cash Flow

-$8.14M

Capital Expenditure

$0.00

Free Cash Flow

-$8.14M

Cash & ST Invst.

$4.68M

Total Debt

$0.00

Enveric Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$37.24K

+54.0%

Gross Margin

0.00%

N/A

Market Cap

$5.89M

N/A

Market Cap/Employee

$1.18M

N/A

Employees

5

N/A

Net Income

-$1.63M

+25.2%

EBITDA

-$1.60M

+24.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.91M

+14.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.49%

N/A

Return on Invested Capital

-1.62%

N/A

Free Cash Flow

-$2.26M

+5.6%

Operating Cash Flow

-$2.26M

+5.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
JSPRJasper Therapeutics, Inc.
$0.46-0.64%
INDPIndaptus Therapeutics, Inc.
$2.40+18.52%
ZVSAZyVersa Therapeutics, Inc.
$0.20+13.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
DSYBig Tree Cloud
$11.74+5.38%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.04-0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.18+0.06%
SMCISuper Micro Computer
$32.40-0.20%

Questions About ENVB

What is the current price of Enveric Biosciences?

Enveric Biosciences is trading at $1.65 per share.

What is the 52-week range for Enveric Biosciences?

Over the past 52 weeks, Enveric Biosciences has traded between $1.60 and $17.64.

How much debt does Enveric Biosciences have?

As of the most recent reporting period, Enveric Biosciences reported total debt of $0.00.

How much cash does Enveric Biosciences have on hand?

Enveric Biosciences reported $4.91M in cash and cash equivalents in its most recent financial results.

What is Enveric Biosciences’s dividend yield?

Enveric Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.